Amgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim rights to an OX40-targeting drug from Kyowa Kirin that is ready for phase 3 testing for atopi
Roche has broken new ground with its ALK inhibitor Alecenesa, becoming the first drug in the class to be approved by the FDA for adjuvant use after surgery in early-stage,
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.